About Summit:

Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.

Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), with three active Phase III trials:

• HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib).

• HARMONi-3 is a Phase III clinical trial which is designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

• HARMONi-7 is a Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting.

Overview of Role:

The Vice President, Global Marketing will serve as the strategic and operational leader responsible for driving the global brand strategy of a high-priority product (ivonescimab) across its lifecycle. This role will shape and execute all aspects of the global marketing plan—from positioning and launch strategy to lifecycle management and market expansion. The position will report to the Chief Commercial Officer.

Role and Responsibilities:

• The role will help define and manage the LCM of the new indications of ivonescimab, with R&D, Regulatory, Company Strategy, US Marketing and Sr Management
• Works with the cross functional team to develop tumor maps of unmet need, future competition and ability to succeed across the Oncology landscape. Identify white space opportunities and unmet needs in current and future markets.
• Provide commercial input into the investment models and valuations
• Serve as the voice of the brand internally and externally, ensuring alignment with corporate objectives and scientific vision
• Develops the LCM pre-launch plans, coordinating timelines, tactics, and performance metrics. Also, develops pre-launches strategies across countries and functional partners
• Drive launch readiness, launch excellence frameworks, and global rollouts in collaboration with regional and local commercial teams
• Serve as the global commercial lead within the cross-functional asset team, collaborating with R&D, Medical Affairs, Market Access, Regulatory, and Clinical Development
• Partner with HEOR and Market Access teams to shape the global value narrative and support pricing and reimbursement strategies
• Synthesize insights from market research, KOLs, competitive intelligence, and stakeholder feedback to continuously evolve and strengthen the brand strategy
• Drive strategic lifecycle planning, including geographic expansion, indication extensions, label updates, and loss-of-exclusivity preparation
• Monitor performance metrics, brand health indicators, and ROI to adjust tactics and optimize investments
• All other duties as assigned

Experience, Education and Specialized Knowledge and Skills:

• Advanced degree in Business, Marketing, Life Sciences, or related field (MBA or equivalent preferred)
• A minimum of 15+ years of experience in pharmaceutical marketing, including leadership of global brands
• Deep understanding of Oncology across various solid tumors including the science and the evolving market landscape
• I/O (immuno-oncology) experience is preferred
• Proven success leading the global commercialization and/or launch of a drug in the oncology space
• Good understanding of marketing principles, customer behavior, and product strategies in oncology
• Deep understanding of global market dynamics, access and reimbursement, and regulatory environments
• Strategic mindset with strong analytical, financial acumen, and communication skills
• Demonstrated ability to lead cross-functional and multicultural teams in a matrix environment
• Experience working closely with regional and affiliate commercial organizations as well as R&D and Regulatory

The pay range for this role is $300,000-$350,000 annually. Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation.

Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit.